Navigation Links
CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Company's Shares
Date:3/12/2008

Split Intended to Maintain Nasdaq Listing and Attract Additional Investors

as Company Enters Next Growth Phase

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that its Board of Directors has approved a resolution proposing a reverse split of 1 for 7 shares of the Company's common stock. The proposed reverse split is expected to become effective, subject to shareholder approval, shortly after the Company's May 8, 2008, Annual Shareholders Meeting.

In the reverse split, each seven (7) shares of CardioDynamics common stock issued and outstanding will be combined into one (1) share of common stock, which initially should have the effect of proportionately increasing the stock price. Following the reverse split, the total number of shares outstanding will be reduced to approximately 7.2 million shares. Additionally, the reverse split will affect all shares of CardioDynamics common stock proportionally, including its Convertible Notes and outstanding stock options.

Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "Recently, a number of our largest shareholders have expressed overwhelming support to affect a reverse split to maintain our Nasdaq listing and attract a greater level of interest among investors and analysts. We also believe the reverse split comes at an excellent time and is complementary with the positive turnaround occurring in our business. Not only do we think the capital structure, post-reverse split, will be more attractive to potential investors, but our recent four consecutive quarters of revenue growth, international sales momentum, continued growth plan for 2008, and intense focus on achieving positive operating cash flow by the fourth quarter of 2008, should all be positive catalysts for new investors."

In November, 2007, the Company transferred to the Nasdaq Capital Market and has until April 14, 2008, to maintain a minimum bid price of $1.00 per share for 10 or more consecutive days in order to meet the continued listing requirements. The Company anticipates receiving a notice of noncompliance in April, 2008, and if so, will request a hearing with Nasdaq to present its plan to achieve compliance which will include the intention to seek prompt shareholder approval of the reverse stock split.

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at http://www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press release contains forward-looking statements, such as potential Nasdaq listing compliance, future growth and positive cash flow beliefs, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ(R) product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
2. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
3. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
4. Alexander M. Cutler Nominated for Election to DuPont Board of Directors
5. Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors
6. Hospital Caregivers Unveil Billboards Calling for Improved Patient Care, Quality Jobs at Community Medical Centers
7. First-Ever National Board Certification(R) for Americas Health Educators Arrives
8. Ventas Appoints James D. Shelton and Robert D. Reed to Board
9. Former Federal Reserve Chairman Paul Volcker To Join Board of Directors of Still River Systems
10. DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Companys Melanoma Advisory Board
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... ... us, but there are things we can do to improve the odds of staying healthy for ... that there are simple, yet important steps that can be taken to maintain good health and ... her patients include;, , exercise , healthy diet , ...
(Date:4/29/2016)... ... 30, 2016 , ... World Patent Marketing , a ... an automotive invention that improves the storage features of a pick up truck. ... Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over the next ...
(Date:4/29/2016)... , ... April 29, 2016 , ... In an ... and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent in ... youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial ... for Graduate Medical Education (ACGME) that it has received accreditation for its residency ... of three residency programs that Memorial is currently pursuing, including Pediatrics and Internal ...
(Date:4/29/2016)... ... 2016 , ... Our bodies are bombarded daily by environmental and lifestyle factors ... stressors is to adopt a more healthful diet, but too many people think that ... Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
Breaking Medicine Technology: